Lazard Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
Lazard Asset Management's XENE Position: Q3 2026 in Review
Lazard Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 18% in Q3 2026, buying an estimated $478K and bringing the position to 52,177 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #976.
Lazard Asset Management first reported a position in XENE in Q3 2020 and has held it in 5 quarters since. The position peaked at $3.53M in Q4 2025. 288 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- Lazard Asset Management held 52,177 shares of Xenon Pharmaceuticals worth $1.94M as of Q3 2026.
- Lazard Asset Management bought 8,052 Xenon Pharmaceuticals shares in Q3 2026, an estimated $478K.
- Xenon Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #976 holding.
- Lazard Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2020 and has held it in 5 quarters since.
- Lazard Asset Management's Xenon Pharmaceuticals position peaked at $3.53M in Q4 2025.
- 288 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.